Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fuda Cancer Hospital, Guangzhou
By enrolling patients with breast cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）for breast cancer.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Age:18-80
2. Karnofsky performance status \>60
3. Diagnosis of breast cancer based on histology or the current accepted radiological measures.
